We at Auris Medical are dedicated to developing novel pharmaceutical products for the treatment of inner ear disorders and mental health supportive care.
We are focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). This program is currently in Phase 1.
In addition Auris Medical has two Phase 3 programs under development: AM-111 for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus.
AM-111 has been granted orphan drug status by the FDA and the EMA.